159 related articles for article (PubMed ID: 12528801)
1. Chemosensitivity testing in malignant melanoma.
Ugurel S; Tilgen W; Reinhold U
Recent Results Cancer Res; 2003; 161():81-92. PubMed ID: 12528801
[TBL] [Abstract][Full Text] [Related]
2. Treosulfan in the treatment of metastatic melanoma: from chemosensitivity testing to clinical trials.
Neuber K
Recent Results Cancer Res; 2003; 161():159-79. PubMed ID: 12528807
[TBL] [Abstract][Full Text] [Related]
3. Heterogeneity of chemosensitivity of metastatic cutaneous melanoma.
Cree IA; Neale MH; Myatt NE; de Takats PG; Hall P; Grant J; Kurbacher CM; Reinhold U; Neuber K; MacKie RM; Chana J; Weaver PC; Khoury GG; Sartori C; Andreotti PE
Anticancer Drugs; 1999 Jun; 10(5):437-44. PubMed ID: 10477162
[TBL] [Abstract][Full Text] [Related]
4. In vitro drug sensitivity predicts response and survival after individualized sensitivity-directed chemotherapy in metastatic melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group.
Ugurel S; Schadendorf D; Pföhler C; Neuber K; Thoelke A; Ulrich J; Hauschild A; Spieth K; Kaatz M; Rittgen W; Delorme S; Tilgen W; Reinhold U;
Clin Cancer Res; 2006 Sep; 12(18):5454-63. PubMed ID: 17000680
[TBL] [Abstract][Full Text] [Related]
5. Comparison of the ex vivo chemosensitivity of uveal and cutaneous melanoma.
Neale MH; Myatt NE; Khoury GG; Weaver P; Lamont A; Hungerford JL; Kurbacher CM; Hall P; Corrie PG; Cree IA
Melanoma Res; 2001 Dec; 11(6):601-9. PubMed ID: 11725206
[TBL] [Abstract][Full Text] [Related]
6. [Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].
Zhao D; Zhang W; Li XG; Wang XB; Zhang LF; Li M; Li YF; Tian HM; Song PP; Liu J; Chang QY; Wu LY
Zhonghua Fu Chan Ke Za Zhi; 2011 Mar; 46(3):193-8. PubMed ID: 21575453
[TBL] [Abstract][Full Text] [Related]
7. The chemosensitivity profile of retinoblastoma.
Di Nicolantonio F; Neale M; Onadim Z; Hungerford JL; Kingston JL; Cree IA
Recent Results Cancer Res; 2003; 161():73-80. PubMed ID: 12528800
[TBL] [Abstract][Full Text] [Related]
8. The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy.
Parker KA; Glaysher S; Polak M; Gabriel FG; Johnson P; Knight LA; Poole M; Narayanan A; Hurren J; Cree IA
J Clin Pathol; 2010 Nov; 63(11):1012-20. PubMed ID: 20924094
[TBL] [Abstract][Full Text] [Related]
9. Heterogeneity of chemosensitivity of colorectal adenocarcinoma determined by a modified ex vivo ATP-tumor chemosensitivity assay (ATP-TCA).
Whitehouse PA; Knight LA; Di Nicolantonio F; Mercer SJ; Sharma S; Cree IA;
Anticancer Drugs; 2003 Jun; 14(5):369-75. PubMed ID: 12782944
[TBL] [Abstract][Full Text] [Related]
10. Heterogeneity of chemosensitivity in esophageal cancer using ATP-tumor chemosensitivity assay.
Ling ZQ; Qi CJ; Lu XX; Qian LJ; Gu LH; Zheng ZG; Zhao Q; Wang S; Fang XH; Yang ZX; Yin J; Mao WM
Acta Pharmacol Sin; 2012 Mar; 33(3):401-6. PubMed ID: 22286916
[TBL] [Abstract][Full Text] [Related]
11. The ex vivo chemosensitivity profile of choroidal melanoma.
Myatt N; Cree IA; Kurbacher CM; Foss AJ; Hungerford JL; Plowman PN
Anticancer Drugs; 1997 Sep; 8(8):756-62. PubMed ID: 9396619
[TBL] [Abstract][Full Text] [Related]
12. Chemosensitivity testing using microplate adenosine triphosphate-based luminescence measurements.
Kurbacher CM; Cree IA
Methods Mol Med; 2005; 110():101-20. PubMed ID: 15901931
[TBL] [Abstract][Full Text] [Related]
13. ATP chemosensitivity testing in ovarian and breast cancer: early clinical trials.
Kurbacher CM; Grecu OM; Stier U; Gilster TJ; Janát MM; Untch M; Konecny G; Bruckner HW; Cree IA
Recent Results Cancer Res; 2003; 161():221-30. PubMed ID: 12528810
[TBL] [Abstract][Full Text] [Related]
14. Chemosensitivity testing of human malignant melanoma. A retrospective analysis of clinical response and in vitro drug sensitivity.
Schadendorf D; Worm M; Algermissen B; Kohlmus CM; Czarnetzki BM
Cancer; 1994 Jan; 73(1):103-8. PubMed ID: 7506115
[TBL] [Abstract][Full Text] [Related]
15. [Correlation between ATP bioluminescence tumor chemosensitivity assay and clinical response in ovarian cancer].
Tian HM; Shi XY; Fu J; Chao DY; Zhang K; Wu LY; Wang JW; Zhang W
Zhonghua Zhong Liu Za Zhi; 2005 May; 27(5):296-8. PubMed ID: 15996325
[TBL] [Abstract][Full Text] [Related]
16. In vitro chemosensitivity in breast cancer using ATP-tumor chemosensitivity assay.
Qi CJ; Ning YL; Zhu YL; Min HY; Ye H; Qian KQ
Arch Pharm Res; 2009 Dec; 32(12):1737-42. PubMed ID: 20162402
[TBL] [Abstract][Full Text] [Related]
17. Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo.
Neuber K; tom Dieck A; Blödorn-Schlicht N; Itschert G; Karnbach C
Melanoma Res; 1999 Apr; 9(2):125-32. PubMed ID: 10380934
[TBL] [Abstract][Full Text] [Related]
18. Chemosensitivity testing as an aid to anti-cancer drug and regimen development.
Cree IA
Recent Results Cancer Res; 2003; 161():119-25. PubMed ID: 12528804
[TBL] [Abstract][Full Text] [Related]
19. Use of an ex vivo ATP luminescence assay to direct chemotherapy for recurrent ovarian cancer.
Kurbacher CM; Cree IA; Bruckner HW; Brenne U; Kurbacher JA; Müller K; Ackermann T; Gilster TJ; Wilhelm LM; Engel H; Mallmann PK; Andreotti PE
Anticancer Drugs; 1998 Jan; 9(1):51-7. PubMed ID: 9491792
[TBL] [Abstract][Full Text] [Related]
20. [-Chemosensitivity testing in gynecologic oncology. Experiences with an ATP bioluminescence assay-].
Kurbacher CM; Mallmann P; Kurbacher JA; Hübner H; Krebs D
Geburtshilfe Frauenheilkd; 1996 Feb; 56(2):70-8. PubMed ID: 8647362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
